Trial Profile
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects with Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2020
Price :
$35
*
At a glance
- Drugs Urelumab (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 May 2020 Results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631) published in the American Journal of Hematology
- 18 Oct 2016 Results of integrated safety and preliminary pharmacodynamic data analysis from this and other two studies (n=346) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 09 Jun 2016 Status changed from active, no longer recruiting to completed.